Amplitude Surgical Announces H1 2023-2024 Results

€49.1m Sales and €11.8m EBITDA - Seite 2

 

24.1%

25.8%

-167bp

Recurring operating income

5.1

4.9

 

Non-recurring operating income and expenses

-1.1

-1.0

 

Operating income

4.0

3.9

 

Net financial income

-3.9

-6.9

 

Current and deferred taxes

-0.3

-0.3

 

Income from discontinued operations, net of tax

 

-0.9

 

Net income - Group share

-0.2

-4.2

 

 

 

December 31,
2023

June 30,
2023

 

Net financial debt

81.5

69.3

 

Cash position at end of period

31.3

37.2

 

 

EBITDA up +1.5% with an EBITDA margin of 24.1%.

In the 1^st half-year (July - December) of the 2023-24 financial year, Amplitude Surgical sales came to €49.1 million, up +8.5% and +9.4% at constant exchange rates on the previous year.

Amplitude Surgical reported a gross margin of 70.8%, down -86 bp, mainly due to higher product costs.

Group operating expenses came to €22.9m, up 10.4% on the first half of FY 2022-23.

Sales & marketing expenses rose by 7.4%, in line with business growth and salary increases both in France and abroad.

Administrative expenses rose by 17.9% to €7.3m, with higher personnel expenses and regulatory costs. During the 1^st half-year 2023/2024, R&D expenditure remained stable at 0.8 M€, at 1.7% of sales. However, including capitalized R&D expenditure, the Group's overall investment in R&D increased from 2.3 M€ in the first half of the 2022-23 financial year to 3.0 M€ in the first half of the 2023-24 financial year.